Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

EP-100 membrane-disrupting peptide × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1 Gynecologic 1

Conditions

Ovarian Cancer Recurrent 1

Interventions

Paclitaxel 510 Carboplatin 472 Cisplatin 314 Bevacizumab 224 pembrolizumab 203 Gemcitabine 130 olaparib 115 Cyclophosphamide 113 Topotecan 112 liposomal doxorubicin 109 Radiotherapy 106 Taxes 97 Docetaxel 86 Brachytherapy 86 niraparib 80 Doxorubicin 79 Drug Therapy 77 Surveys and Questionnaires 72 Magnetic Resonance Spectroscopy 70 Nivolumab 65 Blood Specimen Collection 63 Specimen Handling 61 Biopsy 60 Hyperthermic Intraperitoneal Chemotherapy 57 fludarabine 52 Letrozole 45 Filgrastim 45 durvalumab 43 Surgical Procedures, Operative 43 Platinum 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01485848 2014-06-10

ESP2011-002

Esperance Pharmaceuticals Inc

Phase 2 Completed

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡